About Fermiscan Limited

Fermiscan is working to develop a world-first innovative test for the detection of breast cancer using hair. The breakthrough technology that underpins the Fermiscan™ Test is the discovery by an Australian scientist that breast cancer can potentially be detected by synchrotron x-ray diffraction of hair. The test is non-invasive and suitable for women from as early as 20 years of age. It may provide early detection of breast cancer thus assist in early treatment. Early detection benefits range from increased survival, increased treatment options and improved quality of life. The Fermiscan™ Test is in trial and not yet available commercially.

Scientific & Medical Advisory Board (SMAB)

Fermiscan has developed an experienced Scientific and Medical Advisory Board (SMAB), to help direct product development and clinical testing programs and to provide independent advice to the Board of Fermiscan.

The Advisory Board provides professional oversight and advice on the commercialisation of the Company's services to ensure they meet the expectations of the medical and patient communities. The composition of the SMAB represents key perspectives and inputs needed in our development programs from both scientists and physicians specialising in various areas of medicine, including radiology.

Specific roles for members of the Advisory Board include:

  • Collaborate with other members of the SMAB to develop methodologies and strategies for using the Fermiscan Test to ensure its use in clinical diagnostic settings is optimised to benefit patient outcomes.
  • Advise Fermiscan's management on appropriate internal and external strategies for communicating scientific and clinical information about the Fermiscan Test to the medical community, government, and public.
  • Develop concepts and protocols for clinical studies which conform to Good Clinical Practice and other international trial requirements.
  • Define medical marketing approaches in alignment with best practice.
  • Advise on publication of studies in peer-reviewed scientific journals.
  • Assist with advising medical professionals, on how to appropriately interpret and use the Fermiscan Test as needed.
  • Foster scientific and clinical information exchange between the medical community and Fermiscan.
  • Provide scientific and clinical support for regulatory and clinical guideline decision makers and national professional standards committees.
  • Evaluate new technologies and opportunities.

 

Scientific and Medical Advisory Board Members

 

Fermiscan will be represented on the SMAB by Dr Peter French, BSc, MSc, PhD, MBA, Science and Innovation Manager.

Dr French is a cell and molecular biologist with a PhD awarded for characterising keratin proteins of the wool fibre. He is a past President of the Australian and New Zealand Society for Cell Biology and is a member of the Board of the International Society for Differentiation.

Two additional members of the Scientific and Medical Advisory Board are Dr Ron Shnier and Dr Michael Carr, both of whom are eminent radiologists. Dr Shnier chairs the SMAB.

 

 

top